Cryptotanshinone attenuates cardiac fibrosis via downregulation of COX-2, NOX-2, and NOX-4

Journal of Cardiovascular Pharmacology

Volumn 64, Issue 1, 2014, Pages 28-37

  Ma, Yunzi ^a   Li, Hong ^a   Yue, Zhongbao ^a   Guo, Jinlei ^a   Xu, Suowen ^b   Xu, Jian ^a   Jia, Yanyan ^a   Yu, Na ^a   Zhang, Boyu ^a   Liu, Shenglan ^a   Liu, Min ^a   Shao, Weiwei ^a   Chen, Shaorui ^a   Liu, Peiqing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

AMI; Ang II; cardiac fibrosis; COX 2; cryptotanshinone; ERK1 2; NOX 2; NOX 4

Indexed keywords

ANGIOTENSIN II; CONNECTIVE TISSUE GROWTH FACTOR; CRYPTOTANSHINONE; CYCLOOXYGENASE 2; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; CYBB PROTEIN, RAT; MEMBRANE PROTEIN; NOX4 PROTEIN, RAT; PHENANTHRENE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ACUTE HEART INFARCTION; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; FIBRINOLYSIS; HEART MUSCLE FIBROSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TISSUE CULTURE; UPREGULATION; ANIMAL; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; FIBROBLAST; FIBROSIS; GENETICS; ISOLATION AND PURIFICATION; MYOCARDIAL INFARCTION; PATHOLOGY; SALVIA MILTIORRHIZA; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; CYCLOOXYGENASE 2; DOWN-REGULATION; FIBROBLASTS; FIBROSIS; MALE; MEMBRANE GLYCOPROTEINS; MYOCARDIAL INFARCTION; NADPH OXIDASE; PHENANTHRENES; RATS; RATS, SPRAGUE-DAWLEY; SALVIA MILTIORRHIZA; UP-REGULATION;

EID: 84904259334     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000086     Document Type: Article

References (55)

1. Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol. 2010;225:631Y637
2. Segura AM, Frazier OH, Buja LM. Fibrosis and heart failure. Heart Fail Rev. 2012;19:173Y185
3. Kanzaki Y, Terasaki F, Okabe M, et al. Myocardial inflammatory cell infiltrates in cases of dilated cardiomyopathy as a determinant of outcome following partial left ventriculectomy. Jpn Circ J. 2001;65:797Y802
4. Ratcliffe NR, Hutchins J, Barry B, et al. Chronic myocarditis induced by T cells reactive to a single cardiac myosin peptide: Persistent inflammation, cardiac dilatation, myocardial scarring and continuous myocyte apoptosis. J Autoimmun. 2000;15:359Y367
5. Hayashidani S, Tsutsui H, Shiomi T, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2003;108: 2134Y2140
6. Scheuren N, Jacobs M, Ertl G, et al. Cyclooxygenase-2 in myocardium stimulation by angiotensin-II in cultured cardiac fibroblasts and role at acute myocardial infarction. J Mol Cell Cardiol. 2002;34:29Y37
7. Saito T, Rodger IW, Hu F, et al. Inhibition of COX pathway in experimental myocardial infarction. J Mol Cell Cardiol. 2004;37:71Y77
8. Deng P, Zhao SP, Dai HY, et al. Atorvastatin reduces the expression of COX-2 mRNA in peripheral blood monocytes from patients with acute myocardial infarction and modulates the early inflammatory response. Clin Chem. 2006;52:300Y303
9. Abbate A, Santini D, Biondi-Zoccai GG, et al. Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: Friend or foe?. Heart. 2004;90:440Y443
10. Abbate A, Limana F, Capogrossi MC, et al. Cyclo-oxygenase-2 (COX-2) inhibition reduces apoptosis in acute myocardial infarction. Apoptosis. 2006;11:1061Y1063
11. Jiang YR, Yin HJ, Lu Y. Effects of propyl gallate on serum inflammatory factors and protein expression of COX-2 and ICAM-1 in ischemic myocardium of rats with acute myocardial infarction. Chin J Integr Med. 2008;28:921Y924
12. Wu R, Laplante M, de Champlain J. Cyclooxygenase-2 inhibitors attenuate angiotensin II induced oxidative stress, hypertension, and cardiac hypertrophy in rats. Hypertension. 2005;45:1139Y1144
13. Saito T, Rodger IW, Hu F, et al. Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun. 2000;273:772Y775
14. Nabeebaccus A, Zhang M, Shah AM. NADPH oxidases and cardiac remodelling. Heart Fail Rev. 2011;16:5Y12
15. Tharaux PL, Chatziantoniou C, Fakhouri F, et al. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension. 2000;36:330Y336
16. Chang C, Zhang C, Zhao X, et al. Differential regulation of mitogenactivated protein kinase signaling pathways in human with different types of mitral valvular disease. J Surg Res. 2013;181:49Y59
17. Zhang JP, Zhang YY, Zhang Y, et al. Salvia miltiorrhiza (Danshen) injection ameliorates iron overload-induced cardiac damage in mice. Planta Med. 2013;79:744Y752
18. Jiang B, Li D, Deng Y, et al. Salvianolic acid A, a novel matrix metalloproteinase-9 inhibitor, prevents cardiac remodeling in spontaneously hypertensive rats. PLoS One. 2013;8:e59621
19. Zhang L, Wu Y, Li Y, et al. Tanshinone IIA improves miR-133 expression through MAPK ERK1/2 pathway in hypoxic cardiac myocytes. Cell Physiol Biochem. 2012;30:843Y852
20. Ling S, Luo R, Dai A, et al. A pharmaceutical preparation of Salvia miltiorrhiza protects cardiac myocytes from tumor necrosis factorinduced apoptosis and reduces angiotensin II-stimulated collagen synthesis in fibroblasts. Phytomedicine. 2009;16:56Y64
21. Suh SJ, Jin UH, Choi HJ, et al. Cryptotanshinone from Salvia miltiorrhiza BUNGE has an inhibitory effect on TNF-alpha-induced matrix metalloproteinase-9 production and HASMC migration via downregulated NF-kappaB and AP-1. Biochem Pharmacol. 2006;72:1680Y 1689
22. Ma S, Yang D, Wang K, et al. Cryptotanshinone attenuates isoprenalineinduced cardiac fibrosis in mice associated with upregulation and activation of matrix metalloproteinase-2. Mol Med Rep. 2012;6:145Y150
23. Jin YC, Kim CW, Kim YM, et al. Cryptotanshinone, a lipophilic compound of Salvia miltiorrhiza root, inhibits TNF-alpha-induced expression of adhesion molecules in HUVEC and attenuates rat myocardial ischemia/ reperfusion injury in vivo. Eur J Pharmacol. 2009;614:91Y97
24. Ichihara S, Senbonmatsu T, Price EJ, et al. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation. 2001;104:346Y351
25. Bouzegrhane F, Thibault G. Is angiotensin II a proliferative factor of cardiac fibroblasts?. Cardiovasc Res. 2002;53:304Y312
26. Kawano H, Do YS, Kawano Y, et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation. 2000;101:1130Y 1137
27. Schnee JM, Hsueh WA. Angiotensin II, adhesion, and cardiac fibrosis. Cadiovasc Res. 2000;46:264Y268
28. Crawford DC, Chobanian AV, Brecher P. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res. 1994;74:727Y739
29. Chen J, Mehta JL. Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: Blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol. 2006;291:H1738Y H1745
30. Zhang H, Pi R, Li R, et al. PPARbeta/delta activation inhibits angiotensin II-induced collagen type I expression in rat cardiac fibroblasts. Arch Biochem Biophys. 2007;460:25Y32
31. Singh P, Carraher C, Schwarzbauer JE. Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Biol. 2010;26:397Y419
32. Leask A. Potential therapeutic targets for cardiac fibrosis: TGF-b, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res. 2010;106:1675Y1680
33. Thandavarayan RA, Watanabe K, Ma M, et al. Dominant-negative p38alpha mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. Am J Physiol Heart Circ Physiol. 2009;297:H911YH919
34. Cucoranu I, Clempus R, Dikalova A, et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res. 2005;97:900Y907
35. Kagiyama S, Matsumura K, Goto K, et al. Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice. Regul Pept. 2010;160: 133Y139
36. Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol. 2010;56:2115Y2125
37. Jin DZ, Yin LL, Ji XQ, et al. Cryptotanshinone inhibits cyclooxygenase-2 enzyme activity but not its expression. Eur J Pharmacol. 2006;549: 166Y172
38. Yagi A. Possible active components of tan-shen (Salvia miltiorrhiza) for protection of the myocardium against ischemia-induced derangements. Planta Med. 1989;55:51Y54
39. Jin HJ, Li CG. Tanshinone IIA and cryptotanshinone prevent mitochondrial dysfunction in hypoxia-induced H9c2 cells: Association to mitochondrial ROS, intracellular nitric oxide, and calcium levels. Evid Based Complement Alternat Med. 2013;2013:610Y694
40. Poli G, Parola M. Oxidative damage and fibrogenesis. Free Radic Biol Med. 1997;22:287Y305
41. Levick SP, Loch DC, Taylor SM, et al. Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J Immunol. 2007;178:641Y646
42. Kania G, Blyszczuk P, Eriksson U. Mechanisms of cardiac fibrosis in inflammatory heart disease. Trends Cardiovasc Med. 2009;19:247Y252
43. Martinez-Revelles S, Avendano MS, Garcia-Redondo AB, et al. Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. Antioxid Redox Signal. 2013; 18:51Y65
44. Liang D, Li F, Fu Y, et al. Thymol inhibits LPS-stimulated inflammatory response via down-regulation of NF-kappaB and MAPK signaling pathways in mouse mammary epithelial cells. Inflammation. 2013;37: 214Y222
45. Wang BH, Bertucci MC, Ma JY, et al. Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone. Clin Exp Pharmacol Physiol. 2010;37:912Y918
46. Sirker A, Zhang M, Murdoch C, et al. Involvement of NADPH oxidases in cardiac remodelling and heart failure. Am J Nephrol. 2007;27:649Y660
47. Gilleron M, Marechal X, Montaigne D, et al. NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochem Biophys Res Commun. 2009;388:727Y731
48. Li J, Stouffs M, Serrander L, et al. The NADPH oxidase NOX4 drives cardiac differentiation: Role in regulating cardiac transcription factors and MAP kinase activation. Mol Biol Cell. 2006;17:3978Y3988
49. Martin A, Perez-Giron JV, Hernanz R, et al. Peroxisome proliferatoractivated receptor-gamma activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress. J Hypertens. 2012;30:315Y326
50. Wang X, Lu J, Khaidakov M, et al. Aspirin suppresses cardiac fibroblast proliferation and collagen formation through downregulation of angiotensin type 1 receptor transcription. Toxicol Appl Pharmacol. 2012;259: 346Y354
51. Sancho P, Martin-Sanz P, Fabregat I. Reciprocal regulation of NADPH oxidases and the cyclooxygenase-2 pathway. Free Radic Biol Med. 2011; 51:1789Y1798
52. Wu R, Laplante MA, de Champlain J. Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats. Hypertension. 2005;45:1139Y1144
53. LaPointe MC, Isenovic E. Interleukin-1beta regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes. Hypertension. 1999; 33:276Y282
54. Qin F, Shite J, Liang CS. Antioxidants attenuate myocyte apoptosis and improve cardiac function in CHF: Association with changes in MAPK pathways. Am J Physiol Heart Circ Physiol. 2003;285: H822YH832
55. Sano M. ERK and p38 MAPK, but not NF-kB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circ Res. 2001;89:661Y669